Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 594

1.

A Conversation Between Hedvig Hricak and Johannes Czernin.

Hricak H, Czernin J.

J Nucl Med. 2019 Aug;60(8):1038-1041. doi: 10.2967/jnumed.119.232405. No abstract available.

PMID:
31371619
2.

Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology.

Nass SJ, Cohen MB, Nayar R, Zutter MM, Balogh EP, Schilsky RL, Hricak H, Elenitoba-Johnson KSJ.

Oncologist. 2019 Jul 31. pii: theoncologist.2019-0261. doi: 10.1634/theoncologist.2019-0261. [Epub ahead of print] No abstract available.

PMID:
31366725
3.

Safe spaces for women in challenging environments.

Özvarış ŞB, Hricak H.

Lancet Glob Health. 2019 Aug;7(8):e1004-e1005. doi: 10.1016/S2214-109X(19)30263-3. No abstract available.

4.

Comparison of Magnetic Resonance Imaging-stratified Clinical Pathways and Systematic Transrectal Ultrasound-guided Biopsy Pathway for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Woo S, Suh CH, Eastham JA, Zelefsky MJ, Morris MJ, Abida W, Scher HI, Sidlow R, Becker AS, Wibmer AG, Hricak H, Vargas HA.

Eur Urol Oncol. 2019 Jun 13. pii: S2588-9311(19)30071-9. doi: 10.1016/j.euo.2019.05.004. [Epub ahead of print] Review.

PMID:
31204311
5.

Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise.

Nass SJ, Cogle CR, Brink JA, Langlotz CP, Balogh EP, Muellner A, Siegal D, Schilsky RL, Hricak H.

J Clin Oncol. 2019 Jul 10;37(20):1690-1694. doi: 10.1200/JCO.18.01970. Epub 2019 May 3. No abstract available.

PMID:
31050908
6.

Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer.

Wibmer AG, Robertson NL, Hricak H, Zheng J, Capanu M, Stone S, Ehdaie B, Brawer MK, Vargas HA.

Abdom Radiol (NY). 2019 Aug;44(8):2864-2873. doi: 10.1007/s00261-019-02023-1.

PMID:
31030245
7.

Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.

Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA.

Eur Urol Oncol. 2019 Mar;2(2):166-173. doi: 10.1016/j.euo.2018.08.011. Epub 2018 Sep 22.

PMID:
31017093
8.

The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI.

Hötker AM, Dappa E, Mazaheri Y, Ehdaie B, Zheng J, Capanu M, Hricak H, Akin O.

AJR Am J Roentgenol. 2019 Apr;212(4):823-829. doi: 10.2214/AJR.18.20295. Epub 2019 Feb 4.

PMID:
30714830
9.

Recommendations for the Initial Cancer Staging MRI Report.

Panicek DM, Hricak H.

J Magn Reson Imaging. 2019 May;49(5):1209-1211. doi: 10.1002/jmri.26528. Epub 2019 Jan 4. No abstract available.

PMID:
30609211
10.

News From the Academy.

Hricak H, Seltzer SE.

Acad Radiol. 2019 Apr;26(4):578. doi: 10.1016/j.acra.2018.11.012. Epub 2018 Dec 6. No abstract available.

PMID:
30528752
11.

Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer.

Meier A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa R, Soslow RA, Sutton EJ, Hricak H, Sala E, Vargas HA.

Abdom Radiol (NY). 2019 Jun;44(6):2040-2047. doi: 10.1007/s00261-018-1840-5.

PMID:
30474722
12.

Accelerating anticancer drug development - opportunities and trade-offs.

Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL.

Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Review.

PMID:
30275514
13.

Global Challenges for Cancer Imaging.

Schlemmer HP, Bittencourt LK, D'Anastasi M, Domingues R, Khong PL, Lockhat Z, Muellner A, Reiser MF, Schilsky RL, Hricak H.

J Glob Oncol. 2018 Sep;4:1-10. doi: 10.1200/JGO.17.00036. Epub 2017 Sep 8.

14.

Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3 Tesla.

Mazaheri Y, Shukla-Dave A, Goldman DA, Moskowitz CS, Takeda T, Reuter VE, Akin O, Hricak H.

Magn Reson Imaging. 2019 Jan;55:93-102. doi: 10.1016/j.mri.2018.08.025. Epub 2018 Aug 31.

PMID:
30176373
15.

Temporal changes in MRI appearance of the prostate after focal ablation.

Hötker AM, Meier A, Mazaheri Y, Zheng J, Capanu M, Chaim J, Sosa R, Coleman J, Hricak H, Akin O.

Abdom Radiol (NY). 2019 Jan;44(1):272-278. doi: 10.1007/s00261-018-1715-9.

PMID:
30069583
16.

Trends in oncologic hybrid imaging.

Wibmer AG, Hricak H, Ulaner GA, Weber W.

Eur J Hybrid Imaging. 2018;2(1):1. doi: 10.1186/s41824-017-0019-6. Epub 2018 Jan 19. Review.

17.

Effect of intravascular contrast agent on diffusion and perfusion fraction coefficients in the peripheral zone and prostate cancer.

Mazaheri Y, Hötker AM, Shukla-Dave A, Akin O, Hricak H.

Magn Reson Imaging. 2018 Sep;51:120-127. doi: 10.1016/j.mri.2018.04.007. Epub 2018 Apr 17.

PMID:
29678542
18.

CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.

Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, Sala E.

AJR Am J Roentgenol. 2018 Apr;210(4):918-926. doi: 10.2214/AJR.17.18254. Epub 2018 Feb 28.

19.

Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications.

Mazaheri Y, Akin O, Hricak H.

World J Radiol. 2017 Dec 28;9(12):416-425. doi: 10.4329/wjr.v9.i12.416. Review.

20.

2016 New Horizons Lecture: Beyond Imaging-Radiology of Tomorrow.

Hricak H.

Radiology. 2018 Mar;286(3):764-775. doi: 10.1148/radiol.2017171503. Epub 2018 Jan 18.

PMID:
29346031
21.

Prostate cancer in 2017: Advances in imaging.

Wibmer AG, Vargas HA, Hricak H.

Nat Rev Urol. 2018 Feb;15(2):81-82. doi: 10.1038/nrurol.2017.210. Epub 2017 Dec 12. No abstract available.

22.

Background, current role, and potential applications of radiogenomics.

Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, Hricak H, Sutton EJ, Morris EA.

J Magn Reson Imaging. 2018 Mar;47(3):604-620. doi: 10.1002/jmri.25870. Epub 2017 Nov 2. Review.

23.

Model selection for high b-value diffusion-weighted MRI of the prostate.

Mazaheri Y, Hötker AM, Shukla-Dave A, Akin O, Hricak H.

Magn Reson Imaging. 2018 Feb;46:21-27. doi: 10.1016/j.mri.2017.10.003. Epub 2017 Oct 12.

24.

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes.

Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, Sala E.

Radiology. 2017 Nov;285(2):472-481. doi: 10.1148/radiol.2017161697. Epub 2017 Jun 16.

25.

Multimodality imaging using proton magnetic resonance spectroscopic imaging and 18F-fluorodeoxyglucose-positron emission tomography in local prostate cancer.

Shukla-Dave A, Wassberg C, Pucar D, Schöder H, Goldman DA, Mazaheri Y, Reuter VE, Eastham J, Scardino PT, Hricak H.

World J Radiol. 2017 Mar 28;9(3):134-142. doi: 10.4329/wjr.v9.i3.134.

26.

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.

Vargas HA, Veeraraghavan H, Micco M, Nougaret S, Lakhman Y, Meier AA, Sosa R, Soslow RA, Levine DA, Weigelt B, Aghajanian C, Hricak H, Deasy J, Snyder A, Sala E.

Eur Radiol. 2017 Sep;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y. Epub 2017 Mar 13.

27.

The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.

Nougaret S, Robertson N, Golia Pernicka J, Molinari N, Hötker AM, Ehdaie B, Sala E, Hricak H, Vargas HA.

Abdom Radiol (NY). 2017 Jul;42(7):1968-1974. doi: 10.1007/s00261-017-1086-7.

28.

Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy.

Robertson NL, Sala E, Benz M, Landa J, Scardino P, Scher HI, Hricak H, Vargas HA.

J Urol. 2017 Jul;198(1):65-70. doi: 10.1016/j.juro.2017.02.071. Epub 2017 Feb 16.

29.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

30.

Differentiation of Clear Cell Renal Cell Carcinoma From Other Renal Cortical Tumors by Use of a Quantitative Multiparametric MRI Approach.

Hötker AM, Mazaheri Y, Wibmer A, Karlo CA, Zheng J, Moskowitz CS, Tickoo SK, Russo P, Hricak H, Akin O.

AJR Am J Roentgenol. 2017 Mar;208(3):W85-W91. doi: 10.2214/AJR.16.16652. Epub 2017 Jan 17.

31.

Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.

Nicolau C, Sala E, Kumar A, Goldman DA, Schoder H, Hricak H, Vargas HA.

AJR Am J Roentgenol. 2017 Apr;208(4):849-853. doi: 10.2214/AJR.16.17133. Epub 2017 Jan 17.

32.

Radiation Brain Drain? The Impact of Demographic Change on U.S. Radiation Protection.

Hricak H, Dauer LT.

Health Phys. 2017 Feb;112(2):126-130. doi: 10.1097/HP.0000000000000602.

PMID:
28027150
33.

Abdominal wall endometriosis: differentiation from other masses using CT features.

Yarmish G, Sala E, Goldman DA, Lakhman Y, Soslow RA, Hricak H, Gardner GJ, Vargas HA.

Abdom Radiol (NY). 2017 May;42(5):1517-1523. doi: 10.1007/s00261-016-0998-y.

34.

Differentiation of Uterine Leiomyosarcoma from Atypical Leiomyoma: Diagnostic Accuracy of Qualitative MR Imaging Features and Feasibility of Texture Analysis.

Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow RA, Abu-Rustum NR, Hricak H, Sala E.

Eur Radiol. 2017 Jul;27(7):2903-2915. doi: 10.1007/s00330-016-4623-9. Epub 2016 Dec 5.

35.

Ornithine Decarboxylase Is Sufficient for Prostate Tumorigenesis via Androgen Receptor Signaling.

Shukla-Dave A, Castillo-Martin M, Chen M, Lobo J, Gladoun N, Collazo-Lorduy A, Khan FM, Ponomarev V, Yi Z, Zhang W, Pandolfi PP, Hricak H, Cordon-Cardo C.

Am J Pathol. 2016 Dec;186(12):3131-3145. doi: 10.1016/j.ajpath.2016.08.021. Epub 2016 Oct 19.

36.

Corrigendum to "Molecular imaging for personalized cancer care" [Mol. Oncol. 6(2) (2012) 182-195].

Kircher MF, Hricak H, Larson SM.

Mol Oncol. 2016 Dec;10(10):1627. doi: 10.1016/j.molonc.2016.09.006. Epub 2016 Oct 2. No abstract available.

37.

Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.

Hashimoto T, Rahul K, Takeda T, Benfante N, Mulhall JP, Hricak H, Eastham JA, Vargas HA.

Urol Oncol. 2016 Dec;34(12):530.e9-530.e14. doi: 10.1016/j.urolonc.2016.07.004. Epub 2016 Sep 22.

38.

Imaging approaches to optimize molecular therapies.

Weissleder R, Schwaiger MC, Gambhir SS, Hricak H.

Sci Transl Med. 2016 Sep 7;8(355):355ps16. doi: 10.1126/scitranslmed.aaf3936. Review. Erratum in: Sci Transl Med. 2016 Dec 14;8(369):369er8.

PMID:
27605550
39.

Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis.

Vargas HA, Schor-Bardach R, Long N, Kirzner AN, Cunningham JD, Goldman DA, Moskowitz CS, Sosa RE, Sala E, Panicek DM, Hricak H.

Abdom Radiol (NY). 2017 Jan;42(1):271-277. doi: 10.1007/s00261-016-0851-3.

40.

Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?

Vargas HA, Martin-Malburet AG, Takeda T, Corradi RB, Eastham J, Wibmer A, Sala E, Zelefsky MJ, Weber WA, Hricak H.

Urol Oncol. 2016 Nov;34(11):482.e5-482.e10. doi: 10.1016/j.urolonc.2016.05.026. Epub 2016 Jun 23.

41.

Prevalence and Correlates of Worry About the Health Harms of Medical Imaging Radiation in the General Population.

Hay JL, Gold GS, Baser RE, Hricak H, Dauer LT.

J Prim Care Community Health. 2016 Oct;7(4):219-25. doi: 10.1177/2150131916648917. Epub 2016 May 9.

42.

How Sure Are You, Doctor? A Standardized Lexicon to Describe the Radiologist's Level of Certainty.

Panicek DM, Hricak H.

AJR Am J Roentgenol. 2016 Jul;207(1):2-3. doi: 10.2214/AJR.15.15895. Epub 2016 Apr 11.

PMID:
27065212
43.

Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours.

Karlo CA, Kou L, Di Paolo PL, Kattan MW, Motzer RJ, Russo P, Tickoo SK, Akin O, Hricak H.

Eur J Cancer. 2016 May;59:57-64. doi: 10.1016/j.ejca.2016.02.012. Epub 2016 Mar 24.

44.

Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival.

Hötker AM, Karlo CA, Zheng J, Moskowitz CS, Russo P, Hricak H, Akin O.

AJR Am J Roentgenol. 2016 May;206(5):1023-30. doi: 10.2214/AJR.15.15369. Epub 2016 Mar 2.

45.

Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI.

Hötker AM, Mazaheri Y, Aras Ö, Zheng J, Moskowitz CS, Gondo T, Matsumoto K, Hricak H, Akin O.

AJR Am J Roentgenol. 2016 Apr;206(4):756-63. doi: 10.2214/AJR.15.14912. Epub 2016 Feb 22.

46.

Prostate MRSI predicts outcome in radical prostatectomy patients.

Zakian KL, Hatfield W, Aras O, Cao K, Yakar D, Goldman DA, Moskowitz CS, Shukla-Dave A, Tehrani YM, Fine S, Eastham J, Hricak H.

Magn Reson Imaging. 2016 Jun;34(5):674-81. doi: 10.1016/j.mri.2016.01.003. Epub 2016 Jan 26.

47.

The expanding landscape of diffusion-weighted MRI in prostate cancer.

Wibmer AG, Sala E, Hricak H, Vargas HA.

Abdom Radiol (NY). 2016 May;41(5):854-61. doi: 10.1007/s00261-016-0646-6. Review.

48.

The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.

Robertson NL, Hricak H, Sonoda Y, Sosa RE, Benz M, Lyons G, Abu-Rustum NR, Sala E, Vargas HA.

Gynecol Oncol. 2016 Mar;140(3):420-4. doi: 10.1016/j.ygyno.2016.01.011. Epub 2016 Jan 11.

49.

Use of DWI in the Differentiation of Renal Cortical Tumors.

Hötker AM, Mazaheri Y, Wibmer A, Zheng J, Moskowitz CS, Tickoo SK, Russo P, Hricak H, Akin O.

AJR Am J Roentgenol. 2016 Jan;206(1):100-5. doi: 10.2214/AJR.14.13923.

50.

Imaging Features of Uncommon Gynecologic Cancers.

Miccò M, Sala E, Lakhman Y, Hricak H, Vargas HA.

AJR Am J Roentgenol. 2015 Dec;205(6):1346-59. doi: 10.2214/AJR.14.12695. Review.

Supplemental Content

Loading ...
Support Center